These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1070 related items for PubMed ID: 18729848

  • 1. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
    Elnachef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD.
    Aliment Pharmacol Ther; 2008 Nov 15; 28(10):1249-58. PubMed ID: 18729848
    [Abstract] [Full Text] [Related]

  • 2. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey.
    Chey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM.
    Aliment Pharmacol Ther; 2006 Mar 01; 23(5):655-68. PubMed ID: 16480405
    [Abstract] [Full Text] [Related]

  • 3. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN, Callaghan R, Allen ME, Rowe IF.
    Rheumatology (Oxford); 2005 Jul 01; 44(7):921-4. PubMed ID: 15827035
    [Abstract] [Full Text] [Related]

  • 4. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF, Oakley SP, Major GA.
    Intern Med J; 2004 Apr 01; 34(4):153-61. PubMed ID: 15086694
    [Abstract] [Full Text] [Related]

  • 5. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 01; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 6. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events.
    Thompson PW, Tee L, McBride J, Quincey D, Strat Liddiard G.
    Rheumatology (Oxford); 2005 Oct 01; 44(10):1308-10. PubMed ID: 15972345
    [Abstract] [Full Text] [Related]

  • 7. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN.
    Rheumatology (Oxford); 2007 Feb 01; 46(2):265-72. PubMed ID: 16844699
    [Abstract] [Full Text] [Related]

  • 8. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group.
    Aliment Pharmacol Ther; 2009 Mar 01; 29(5):481-96. PubMed ID: 19053986
    [Abstract] [Full Text] [Related]

  • 9. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA, Derry S, Phillips CJ, McQuay HJ.
    BMC Musculoskelet Disord; 2006 Oct 20; 7():79. PubMed ID: 17054784
    [Abstract] [Full Text] [Related]

  • 10. Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention.
    Scheiman JM.
    Rev Gastroenterol Disord; 2005 Oct 20; 5 Suppl 2():39-49. PubMed ID: 16369226
    [Abstract] [Full Text] [Related]

  • 11. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
    Moride Y, Ducruet T, Boivin JF, Lavoie F, Rochon S.
    Can J Clin Pharmacol; 2005 Oct 20; 12(2):e201-11. PubMed ID: 15998959
    [Abstract] [Full Text] [Related]

  • 12. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C, Stafford RS, Alexander GC.
    Arch Intern Med; 2005 Jan 24; 165(2):171-7. PubMed ID: 15668363
    [Abstract] [Full Text] [Related]

  • 13. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT.
    Clin Gastroenterol Hepatol; 2006 Nov 24; 4(11):1337-45. PubMed ID: 17088110
    [Abstract] [Full Text] [Related]

  • 14. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ, Benraad HB, Rasker JJ.
    Ned Tijdschr Geneeskd; 2007 May 12; 151(19):1062-7. PubMed ID: 17552414
    [Abstract] [Full Text] [Related]

  • 15. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 16. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
    Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L.
    Am J Med; 2004 Jun 15; 116(12):835-42. PubMed ID: 15178499
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M, Chowienczyk P, Kirkham B.
    Aust Fam Physician; 2005 Nov 15; 34(11):945-8. PubMed ID: 16299629
    [Abstract] [Full Text] [Related]

  • 18. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs.
    Nakashima S, Arai S, Mizuno Y, Yoshino K, Ando S, Nakamura Y, Sugawara K, Koike M, Saito E, Naito M, Nakao M, Ito H, Hamaoka K, Rai F, Asakura Y, Akamatu M, Fujimori K, Inao M, Imai Y, Ota S, Fujiwara K, Shiibashi M.
    Aliment Pharmacol Ther; 2005 Jun 15; 21 Suppl 2():60-6. PubMed ID: 15943849
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP, Gertler R, Fricker R.
    Anesth Analg; 2007 Dec 15; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [Abstract] [Full Text] [Related]

  • 20. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT, Pucino F, Resman-Targoff BH.
    J Pain Palliat Care Pharmacother; 2006 Dec 15; 20(4):11-32. PubMed ID: 17182503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.